Enteris Biopharma to Create Oral Metabolic Peptide in New Partnership

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, today announced the initiation of a clinical manufacturing services agreement with KeyBioscience AG, a wholly-owned subsidiary of Nordic Bioscience, whereby Enteris will leverage its proprietary Peptelligence™ platform to advance the development of a proprietary metabolic peptide for the treatment of various indications, including diabetes, obesity, and other metabolic disorders.

Under the terms of the agreement, Enteris BioPharma will leverage its Peptelligence™ platform to manufacture and characterize three oral tablet prototypes of KeyBioscience’s metabolic peptide, as well as become the exclusive provider of finished product for use in pre-clinical and proof-of-concept clinical trial research.

Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, commented, “This agreement with Nordic Bioscience showcases the value of our Peptelligence™ platform to develop and enable the oral delivery of promising peptide and small molecule therapeutics. Additionally, it highlights our unique ability to partner with global pharmaceutical companies to develop drug products that address significant patient care and market opportunities. We are truly excited to be working with Key Bioscience on this new class of compounds.”

Morten Karsdal, Chief Executive Officer of Nordic Bioscience, remarked, “The ability to deliver our proprietary DACRA peptides orally offers KeyBioscience the potential to bring to market a new therapeutic choice for the treatment of metabolic disorders, which is a significant market opportunity. An oral delivery using Enteris’s Peptelligence™ platform and manufacturing capabilities will be a value driver and a key to success. We look forward to progress with an oral formulation of our DACRA peptides into clinical trials and potential commercialization.”